Standard BioTools Inc. LAB
Regular-session close
After hours · Nov 19, 6:30 PM ET
- YTD
- -52.05%
- 1 year
- -52.05%
5D -0.0453 (-6.87%)
- Market cap
- 242.28M
- Revenue (ttm)
- 155.90M
- Profit margin
- -79.92%
- EPS (ttm)
- -0.09
- Shares out
- 372.26M
- Forward P/E
- -8.50
- YTD return
- -52.05%
- 1-year return
- -52.05%
- Volume
- 909.01K
- Avg volume
- 1.19M
- Open
- 0.562
- Previous close
- 0.57
- Day's range
- 0.562 – 0.6302
- 52-week range
- 0.39 – 1.72
- Beta
- 1.57
- Price target
- 3.08 (+402.4%)
Key statistics
- 50-day average
- 1.87
- 200-day average
- 2.14
- Enterprise value
- 236.50M
- Price / sales
- 4.47
- Price / book
- 1.52
- Revenue growth
- -14.20%
- Free cash flow
- -66.16M
- Total cash
- 28.45M
- Total debt
- 111.65M
- Return on equity
- -37.25%
- Short % of float
- 7.59%
Fundamental scorecard
10 of 25 checks passed on LAB’s reported financials
10of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 3 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2024 | Sep 1, 2024 | -0.08 | -0.05 | +0.03 | +37.50% |
| Jul 31, 2024 | Jun 1, 2024 | -0.06 | -0.08 | -0.02 | -33.33% |
| May 8, 2024 | Mar 1, 2024 | -0.09 | -0.23 | -0.14 | -155.56% |
| Feb 28, 2024 | Dec 1, 2023 | -0.13 | -0.08 | +0.05 | +38.46% |
| Nov 7, 2023 | Sep 1, 2023 | 0.00 | -0.15 | — | — |
| Aug 8, 2023 | Jun 1, 2023 | 0.00 | -0.14 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 31, 2024 | TD Cowen | main | Buy | Buy |
| Aug 1, 2024 | TD Cowen | main | Buy | Buy |
| Apr 16, 2024 | TD Cowen | init | — | Buy |
| Apr 4, 2024 | Jefferies | init | — | Buy |
| Jul 12, 2023 | Keybanc | init | — | Overweight |
About Standard BioTools Inc.
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- standardbio.com
News
Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry Business
12 Health Care Stocks Moving In Monday's After-Market Session
ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools' Microfluidics Business, Now Biomark Scientific
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
Standard BioTools Provides Update on Sale of Mass Cytometry Business
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Proxy and Looming Shareholder Merger Vote --VRME, VAL, LAB and FTHM
INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LAB
Standard BioTools Reports Second Quarter 2026 Financial Results
Your note
Sign in to keep a note on LAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLACK JEFFREY G | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 14, 2024 | 428,298 |
| CAREY THOMAS D | Director | Stock Award(Grant) | Jun 27, 2024 | 43,128 |
| CASDIN ELI | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 18, 2024 | 66,730,900 |
| CASDIN PARTNERS MASTER FUND, L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 26, 2024 | 0 |
| COX TROY M | Director | Stock Award(Grant) | Jun 27, 2024 | 161,820 |
| EGHOLM MICHAEL | Chief Executive Officer | Stock Award(Grant) | May 19, 2024 | 1,531,590 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Casdin Capital, LLC | 19.14% | 71,254,677 | 133.25M | Sep 29, 2024 |
| Viking Global Investors, L.P. | 15.76% | 58,651,170 | 109.68M | Sep 29, 2024 |
| Blackrock Inc. | 6.03% | 22,452,115 | 41.99M | Sep 29, 2024 |
| Vanguard Group Inc | 4.65% | 17,292,092 | 32.34M | Sep 29, 2024 |
| Morgan Stanley | 4.10% | 15,245,461 | 28.51M | Sep 29, 2024 |
| Sumitomo Mitsui Trust Holdings, Inc. | 2.57% | 9,578,563 | 17.91M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.49% | 9,268,380 | 17.33M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.03% | 7,569,238 | 14.15M | Oct 30, 2024 |
| ARK ETF Tr-ARK Genomic Revolution ETF | 1.87% | 6,975,605 | 13.04M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.28% | 4,775,066 | 8.93M | Sep 29, 2024 |
| Morgan Stanley Inst Fund Inc-Inception Port | 0.95% | 3,549,878 | 6.64M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.83% | 3,087,314 | 5.77M | Aug 30, 2024 |
